The study will evaluate safety and efficacy of the Colovac bypass device for ostomy-free anastomosis protection following colorectal surgery
SafeHeal, a leading innovator in the field of digestive surgery and developer of the Colovac device, announces today that it has enrolled the first five patients in its CE mark study. The Colovac device is a unique endoluminal bypass sheath placed in the colon following rectal resection, aimed at significantly improving the recovery of patients after colorectal surgery without the need for an ostomy.
This prospective, single-arm, 15-patient study, was approved at the end of 2017 by the French health authority ANSM. It aims to evaluate the safety and efficacy of Colovac for the protection of colorectal anastomosis in adult patients initially scheduled to receive a diverting ostomy as per standard of care, following colorectal surgery. In the study, patients receive a Colovac device in lieu of the ostomy. The study is currently enrolling more patients at two hospitals in France (Strasbourg and Paris).
The two first procedures were carried out at the Institute of Image-Guided Surgery in Strasbourg in collaboration with the CHRU Strasbourg. They were performed by Dr. Antonio D’Urso, MD, digestive surgeon and principal investigator of the study, and Pr. Mutter, MD, PhD, head of liver and gastrointestinal surgery and co-director of IRCAD, one of the world’s most famous surgery training centers. The three further procedures were performed by Pr. Jérémie Lefèvre MD, PhD, professor of digestive surgery at Hospital Saint-Antoine in Paris.
“We are very excited to be part of this first in-human trial. Colovac has the potential to significantly improve the outcomes and experience of our patients while avoiding diverting stoma for the majority of patients,” said Pr. Lefevre.
“In the two cases we performed, the Colovac procedure was very simple, safe and well received by the patients. We look forward to further participating in the clinical evaluation of this technology,” said Dr. D’Urso, principal investigator.
Based on this early experience, the trial confirms the good usability of the device, its placement and retrieval, in line with preclinical experiments. Colovac was well tolerated by patients.
“There is a high clinical and economic need for a disruptive product such as Colovac, which effectively reduces anastomotic leakage rates following colorectal surgery while avoiding the distressing impacts of an ostomy for patients. This trial is a significant milestone in moving SafeHeal towards regulatory approval in Europe and the US,” said Karl Blohm, CEO of SafeHeal.